High Density Lipoproteins

Montecucco F, Favari E, Norata GD, Ronda N, Nofer JR, Vuilleumier N, Fabrizio Montecucco, Elda Favari, Giuseppe Danilo Norata, Nicoletta Ronda, Jerzy-Roch Nofer, Nicolas Vuilleumier, Montecucco, Fabrizio, Favari, Elda, Norata, Giuseppe Danilo, Ronda, Nicoletta, Nofer, Jerzy-Roch, Vuilleumier, Nicolas

Arnold von Eckardstein, Dimitris Kardassis

The cholesterol of high-density lipoproteins (HDLs) and its major proteic component, apoA-I, have been widely investigated as potential predictors of acute cardiovascular (CV) events. In particular, HDL cholesterol levels were shown to be inversely and independently associated with the risk of acute CV diseases in different patient populations, including autoimmune and chronic inflammatory disorders. Some relevant and direct anti-inflammatory activities of HDL have been also recently identified targeting both immune and vascular cell subsets. These studies recently highlighted the improvement of HDL function (instead of circulating levels) as a promising treatment strategy to reduce inflammation and associated CV risk in several diseases, such as systemic lupus erythematosus and rheumatoid arthritis. In these diseases, anti-inflammatory treatments targeting HDL function might improve both disease activity and CV risk. In this narrative review, we will focus on the pathophysiological relevance of HDL and apoA-I levels/functions in different acute and chronic inflammatory pathophysiological conditions.